[go: up one dir, main page]

RU2002109236A - Controlled Release Compositions for Oral Administration - Google Patents

Controlled Release Compositions for Oral Administration

Info

Publication number
RU2002109236A
RU2002109236A RU2002109236/14A RU2002109236A RU2002109236A RU 2002109236 A RU2002109236 A RU 2002109236A RU 2002109236/14 A RU2002109236/14 A RU 2002109236/14A RU 2002109236 A RU2002109236 A RU 2002109236A RU 2002109236 A RU2002109236 A RU 2002109236A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
oral administration
film
controlled release
Prior art date
Application number
RU2002109236/14A
Other languages
Russian (ru)
Other versions
RU2281758C2 (en
Inventor
Раджен ШАХ
Сатиш Чандра КХАННА
Оскар Кальб
Йерг ОГОРКА
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9923045.0A external-priority patent/GB9923045D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2002109236A publication Critical patent/RU2002109236A/en
Application granted granted Critical
Publication of RU2281758C2 publication Critical patent/RU2281758C2/en

Links

Claims (7)

1. Фармацевтическая композиция, включающая ядро, содержащее ривастигмин в качестве фармацевтического действующего вещества и покрытие, где покрытие включает внутреннюю пленку и внешнюю пленку.1. A pharmaceutical composition comprising a core comprising rivastigmine as a pharmaceutical active ingredient and a coating, wherein the coating comprises an inner film and an outer film. 2. Фармацевтическая композиция по п.1, где внутренняя пленка имеет форму мембраны, которая является полупроницаемой для воды или общей воды организма.2. The pharmaceutical composition according to claim 1, where the inner film is in the form of a membrane that is semi-permeable to water or total body water. 3. Фармацевтическая композиция по п.1 или 2, где внешняя пленка проницаема для воды или общей воды организма.3. The pharmaceutical composition according to claim 1 or 2, where the outer film is permeable to water or total body water. 4. Фармацевтическая композиция по любому из пп.1-3, где пленка имеет толщину от 50 до 800 мкм.4. The pharmaceutical composition according to any one of claims 1 to 3, where the film has a thickness of from 50 to 800 microns. 5. Фармацевтическая композиция по любому из пп.1-4, где из ядра высвобождается эффективная доза действующего вещества в течение 6-12 ч после приема внутрь.5. The pharmaceutical composition according to any one of claims 1 to 4, wherein an effective dose of the active substance is released from the core within 6-12 hours after ingestion. 6. Фармацевтическая композиция, из которой высвобождение происходит в виде двух импульсов, включающая композицию по любому из пп.1-5.6. A pharmaceutical composition from which release occurs in the form of two pulses, comprising the composition according to any one of claims 1 to 5. 7. Применение ривастигмина и эксципиентов по любому из пп.1-6 для приготовления лекарственного средства, предназначенного для лечения пациентов, страдающих деменцией типа Альцгеймера от малой до средней тяжести, путем перорального введения.7. The use of rivastigmine and excipients according to any one of claims 1 to 6 for the preparation of a medicament intended for the treatment of patients suffering from moderate to moderate Alzheimer's type dementia by oral administration.
RU2002109236/15A 1999-09-29 2000-09-27 Controlled-release compositions for oral using RU2281758C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9923045.0 1999-09-29
GBGB9923045.0A GB9923045D0 (en) 1999-09-29 1999-09-29 New oral formulations

Publications (2)

Publication Number Publication Date
RU2002109236A true RU2002109236A (en) 2003-11-27
RU2281758C2 RU2281758C2 (en) 2006-08-20

Family

ID=10861819

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002109236/15A RU2281758C2 (en) 1999-09-29 2000-09-27 Controlled-release compositions for oral using

Country Status (31)

Country Link
US (2) US20060246101A1 (en)
EP (1) EP1216032B1 (en)
JP (1) JP2003510268A (en)
KR (2) KR20050100710A (en)
CN (1) CN1213737C (en)
AR (1) AR025792A1 (en)
AT (1) ATE384517T1 (en)
AU (1) AU769646B2 (en)
BR (1) BR0014440A (en)
CA (1) CA2379595A1 (en)
CO (1) CO5210867A1 (en)
CY (1) CY1107923T1 (en)
CZ (1) CZ301455B6 (en)
DE (1) DE60037897T2 (en)
DK (1) DK1216032T3 (en)
EC (1) ECSP003685A (en)
ES (1) ES2299438T3 (en)
GB (1) GB9923045D0 (en)
HU (1) HUP0202744A3 (en)
IL (2) IL148908A0 (en)
MY (1) MY128759A (en)
NO (1) NO331480B1 (en)
NZ (1) NZ517335A (en)
PE (1) PE20010568A1 (en)
PL (1) PL200822B1 (en)
PT (1) PT1216032E (en)
RU (1) RU2281758C2 (en)
SK (1) SK286651B6 (en)
TR (1) TR200200683T2 (en)
WO (1) WO2001022944A1 (en)
ZA (1) ZA200202369B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
EP2431026A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
ES2355735T5 (en) 2004-08-13 2014-06-27 Boehringer Ingelheim International Gmbh Formulation in extended-release tablets containing pramipexole or a pharmaceutically acceptable salt thereof, method of manufacture and use
JP2008525313A (en) * 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-dementia drug stabilization method
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
CN101797236B (en) * 2010-03-23 2012-05-23 西南大学 Rivastigmine orally disintegration tablet and preparation method thereof
KR101869114B1 (en) 2010-09-20 2018-06-19 다이앤 골 Microencapsulation process and product
KR101990951B1 (en) 2015-04-27 2019-06-20 주식회사 네비팜 A sustained releasing Pharmaceutical Composition comprising Rivastigmine
CN106000294B (en) * 2016-07-04 2019-04-30 三峡大学 A kind of bentonite with high expansion and low shrinkage rate and preparation method thereof
CN115192538B (en) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 Compression-coated nifedipine sustained-release tablet and preparation method thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (en) * 1984-09-06 1984-09-06 Ferrosan Ab CONTROLLED-RELEASE MEDICAL PREPARATIONS
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DE3805744C2 (en) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate for the inhibition of acetylcholinesterase
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US4984807A (en) * 1990-01-12 1991-01-15 Baruch Shiryon Board game
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
WO1992002212A2 (en) * 1990-08-07 1992-02-20 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
ATE195252T1 (en) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh DRUG DELIVERY DEVICE WITH CONTROLLED RELEASE
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
CN1158071C (en) * 1997-05-30 2004-07-21 渗透有限公司 Multi-layered osmotic device
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
TR200100931T2 (en) * 1998-10-01 2001-10-22 Novartis Ag New sustained release oral formulations
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system

Similar Documents

Publication Publication Date Title
RU2404750C2 (en) Composition containing base or coat for moderated release and antagonist of nmda receptor, method for introduction of such nmda antagonist to individual
RU96112139A (en) PHARMACEUTICAL DRUG FOR ORAL RECEPTION
HK33793A (en) Oral sustained release forms of carbamazepine
ATE261301T1 (en) MEDICINAL PREPARATIONS CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
RU2003116058A (en) COMPOSITIONS OF A HYDROCODON WITH CONTROLLED RELEASE
RU2001111887A (en) COMPOSITION AS A LOT OF PARTICLES WITH MODIFIED RELEASE
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
RU2002113921A (en) Controlled Release Formulations of Hydrocodone
ATE198152T1 (en) ORAL MEDICINAL PREPARATION WITH DELAYED RELEASE OF ACTIVE INGREDIENTS
CA2459165A1 (en) Dosage forms having prolonged active ingredient release
US5863941A (en) Method and composition of a topical treatment of inner ear and labyrinth symptoms
RU2002109236A (en) Controlled Release Compositions for Oral Administration
CA2366841A1 (en) Tolperisone-containing pharmaceutical preparation for oral administration
RU2001107149A (en) TAUROLIDINE AND / OR TAURULTS AGAINST INFECTIOUS ULCER DISEASE OR INFECTIOUS GASTRITIS
RU2003100507A (en) PHARMACEUTICAL COMPOSITIONS
RU2004109920A (en) PHARMACEUTICAL COMPOSITION INCLUDING LUMIRACOXIB
JPS61183220A (en) Analgesic medicinal composition, manufacture and use
RU2003109606A (en) PHARMACEUTICAL COMPOSITIONS
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
CA2386547C (en) Orally disintegrating composition comprising mirtazapine
RU2001118854A (en) OPTICALLY ACTIVE DERIVATIVE OF Pyridyl-4H-1,2,4-Oxadiazine AND ITS APPLICATION FOR TREATMENT OF VASCULAR DISEASES
JP2003500435A5 (en)
CZ277995A3 (en) Pilocarpine controlled release system
CO5210867A1 (en) SOLID ORAL PHARMACEUTICAL FORMULATION OF CONTROLLED RELEASE OF RIVASTIGMINA WITH COVERING THAT INCLUDES TWO FILMS
EE03954B1 (en) Method for the preparation of the carbamazepine sustained release dosage form